• Long-term revenue targets: The company reiterated its FY27 volume growth guidance of 10% to 15% and remains confident in reaching its Rs 3,000 crore revenue target by the end of FY28.
• Operating margin outlook: EBITDA margins of 22% to 24% remain sustainable, supported by integrated facilities and the full pass-through of higher raw material costs to customers following West Asia disruptions.
• Product pipeline expansion: Upcoming capacity additions include Dimethyl Ether (DME)—expected to add at least Rs 200 crore in revenue next year—along with new plants for acetonitrile, NMM, and import-substitute derivatives like DETA and TEPA.
• Hotel business strategy: The company plans to retain its hotel segment rather than divest it, as the business has supported bottom-line growth over the past two years amid strong industry demand.